Abstract: Objective To investigate the clinical characteristics of intestinal obstruction induced by bortezomib in multiple myeloma patients, so as to provide reference for clinical safe drug use. Methods A retrospective method was used to collect and analyze the incidence of intestinal obstruction in 673 patients with multiple myeloma who received bortezomib from January 2014 to December 2018 in the Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences. Results A total of 42 multiple myeloma patients suffered from intestinal obstruction after treatment with bortezomib. There were no significant differences in gender and age between MM patients who used bortezomib with intestinal obstruction and without intestinal obstruction during the same period (P>0.05).All cases showed partial intestinal obstruction. The median occurrence chemotherapy course was the second (1~8) course of treatment with bortezomib. Among them, 21 patients (50%) used serotonin receptor antagonist antiemetics when using bortezomib. Twenty-nine patients (69.05%) complicated with infection before intestinal obstruction, and all of them were given broad-spectrum antibacterial drugs. In addition, 15 (35.71%) of them were combined with triazole antifungal drugs. After conservative medical treatment, most patients (35 cases, 83.33%) had remission of intestinal obstruction symptoms after one week. After remission of intestinal obstruction, 7 patients were adjusted to chemotherapy reducing the dose of bortezomib, and 5 patients were adjusted to chemotherapy without bortezomib. Conclusion Once intestinal obstruction occurred in the treatment with bortezomib in multiple myeloma patients, it often prevented the progress of chemotherapy remedy. Therefore, it is necessary to strengthen drug education and actively prevent the occurrence of intestinal obstruction, so as to improve the safety of medication.

Key words: multiple myeloma, bortezomib, intestinal obstruction, adverse drug reaction, retrospective analysis